Jose M. Padron
Basic info is private.
Research Keywords and Expertise
CKT0353;a novel microtubule targeting agent;overcomes paclitaxel induced resistance in cancer cells
Interests
Drug discovery; Molecular pharmacology; Anticancer drugs; Chemical databases
Latest Publications
- Open Access ReviewInhibition of Glutamine Metabolism as a Therapeutic Approach Against Pancreatic Ductal AdenocarcinomaX. Fernandes Miguel, M. Padrón JoséJ. Mol. Clin. Med. 2019, 2(4), 97–110; https://doi.org/10.31083/j.jmcm.2019.04.512161Downloads1Citations123Views
- Open Access Original ResearchNaphthol-derived Betti bases as potential SLC6A14 blockersPuerta Adrián, R. Galán Alexis, Abdilla Roderick, Demanuele Kaylie, ... M. Padrón JoséJ. Mol. Clin. Med. 2019, 2(2), 35–40; https://doi.org/10.31083/j.jmcm.2019.02.718166Downloads10Citations158Views
- Open Access Research articleFacts and myths of selective casein kinase 1 ε inhibitionAdrián Puerta, Alexis R. Galán, Miguel X. Fernandes, José M. PadrónJ. Mol. Clin. Med. 2018, 1(4), 195–200; https://doi.org/10.31083/j.jmcm.2018.04.40133Downloads94Views
- Open Access Research articleA Small Molecule Tubulin Depolymerizing Agent Identified by a Phenotypic Drug Discovery ApproachCarla Ríos-Luci, Elena Díaz-Rodríguez, Rubén M. Buey, Inês J. Sousa, ... José M. PadrónJ. Mol. Clin. Med. 2018, 1(2), 67–76; https://doi.org/10.31083/j.jmcm.2018.02.00323Downloads66Views
- Research articleDifferential mechanism of action of the CK1$\varepsilon $ inhibitor GSD0054Irene Lagunes, Elva Martín-Batista, Gastón Silveira-Dorta, Miguel X. Fernandes, José M. PadrónJ. Mol. Clin. Med. 2018, 1(2), 77–84; https://doi.org/10.31083/j.jmcm.2018.02.00430Downloads1Citations96Views